Inhibiting tyrosine kinases: successes and limitations.

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

Seminal studies with STI-571 and Herceptin in chronic myeloid leukemia, gastrointestinal stromal tumors, and breast cancer have clearly demonstrated that blockade of pathogenic tyrosine kinases can alter the natural history of appropriately selected human tumors. On the other hand, trials with EGF receptor inhibitors in unselected populations have shown anywhere from modest to no clinical activity. I will contrast below aspects in the development of inhibitors of Abl, c-Kit, HER2/neu (erbB2), and EGFR, highlight successes and pitfalls in this field, and propose some approaches for the future development of tyrosine kinase inhibitors in human cancer.

Original languageEnglish (US)
JournalCancer biology & therapy
Volume2
Issue number4 Suppl 1
StatePublished - Jul 1 2003

Fingerprint

Protein-Tyrosine Kinases
Gastrointestinal Stromal Tumors
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Natural History
Epidermal Growth Factor Receptor
Neoplasms
Breast Neoplasms
Population
Imatinib Mesylate
Trastuzumab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Inhibiting tyrosine kinases : successes and limitations. / Arteaga, Carlos L.

In: Cancer biology & therapy, Vol. 2, No. 4 Suppl 1, 01.07.2003.

Research output: Contribution to journalReview article

@article{2855b5b07bc249a7bf97499523586acd,
title = "Inhibiting tyrosine kinases: successes and limitations.",
abstract = "Seminal studies with STI-571 and Herceptin in chronic myeloid leukemia, gastrointestinal stromal tumors, and breast cancer have clearly demonstrated that blockade of pathogenic tyrosine kinases can alter the natural history of appropriately selected human tumors. On the other hand, trials with EGF receptor inhibitors in unselected populations have shown anywhere from modest to no clinical activity. I will contrast below aspects in the development of inhibitors of Abl, c-Kit, HER2/neu (erbB2), and EGFR, highlight successes and pitfalls in this field, and propose some approaches for the future development of tyrosine kinase inhibitors in human cancer.",
author = "Arteaga, {Carlos L.}",
year = "2003",
month = "7",
day = "1",
language = "English (US)",
volume = "2",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "4 Suppl 1",

}

TY - JOUR

T1 - Inhibiting tyrosine kinases

T2 - successes and limitations.

AU - Arteaga, Carlos L.

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Seminal studies with STI-571 and Herceptin in chronic myeloid leukemia, gastrointestinal stromal tumors, and breast cancer have clearly demonstrated that blockade of pathogenic tyrosine kinases can alter the natural history of appropriately selected human tumors. On the other hand, trials with EGF receptor inhibitors in unselected populations have shown anywhere from modest to no clinical activity. I will contrast below aspects in the development of inhibitors of Abl, c-Kit, HER2/neu (erbB2), and EGFR, highlight successes and pitfalls in this field, and propose some approaches for the future development of tyrosine kinase inhibitors in human cancer.

AB - Seminal studies with STI-571 and Herceptin in chronic myeloid leukemia, gastrointestinal stromal tumors, and breast cancer have clearly demonstrated that blockade of pathogenic tyrosine kinases can alter the natural history of appropriately selected human tumors. On the other hand, trials with EGF receptor inhibitors in unselected populations have shown anywhere from modest to no clinical activity. I will contrast below aspects in the development of inhibitors of Abl, c-Kit, HER2/neu (erbB2), and EGFR, highlight successes and pitfalls in this field, and propose some approaches for the future development of tyrosine kinase inhibitors in human cancer.

UR - http://www.scopus.com/inward/record.url?scp=1542751704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542751704&partnerID=8YFLogxK

M3 - Review article

C2 - 14508084

AN - SCOPUS:1542751704

VL - 2

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 4 Suppl 1

ER -